Please login to the form below

Not currently logged in
Email:
Password:

heart attack patients

This page shows the latest heart attack patients news and features for those working in and with pharma, biotech and healthcare.

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales

with a prior heart attack and inflammatory atherosclerosis when added to standard therapy. ... Novartis' chief medical officer Vas Narasimhan is hopeful. "Despite current treatment, about 25% of heart attack survivors will have another cardiovascular

Latest news

  • New outcomes data could unlock Repatha's potential, says Amgen New outcomes data could unlock Repatha's potential, says Amgen

    In the four-year FOURIER trial - which involved 27, 500 patients - the drug significantly reduced the risk of heart attack, stroke and death in patients with heart disease in patients with ... The findings back up an earlier, smaller study ( GLAGOV),

  • Novartis boosts cardiovascular pipeline with $1bn Ionis deal Novartis boosts cardiovascular pipeline with $1bn Ionis deal

    The agreement covers drugs designed to reduce two well-characterised factors - lipoprotein(a) and apolipoprotein CIII - that elevate the risk of serious complications such as heart attack and stroke in patients ... Aside from the new additions, Novartis

  • Bayer helps bankroll new stem cell company BlueRock Bayer helps bankroll new stem cell company BlueRock

    of its early projects will be to explore the use of PSCs to regenerate heart muscle in patients who have had a heart attack. ... regeneration in heart attack and heart failure patients.

  • NICE backs expanded use of Brilique in final guidance NICE backs expanded use of Brilique in final guidance

    NICE backs expanded use of Brilique in final guidance. AZ’ s maintenance therapy recommended for long-term use, post-heart attack. ... NICE has recommended AstraZeneca's Brilique (ticagrelor) as a long-term treatment for patients who have had a heart

  • NICE backs use of AZ's Brilique as maintenance therapy NICE backs use of AZ's Brilique as maintenance therapy

    NICE backs use of AZ's Brilique as maintenance therapy. Drug to be used with asprin as treatment for heart attack patients. ... The value of longer-term use in heart attack patients was revealed in the PEGASUS trial, which showed Brilinta plus low-dose

More from news
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Proving real-world value Proving real-world value

    Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”. ... We create thousands of patient leaflets

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics